Roggwil, November 7, 2022 – In the month of October, the threshold of 1,000 inquiries at tinniwell was exceeded for the first time; there were exactly 1,085. This was an increase of 76% within a year.

The cause of this is that the number of patients suffering from long-COVID-related tinnitus has increased explosively. The current mutation BQ.1.1 cannot be stopped by vaccinations and previously overcome infections. Experts anticipate that by the end of November, 37% of new infections will be attributed to this variant. Notably, this variant behaves more aggressively than the mutations in the summer. In practice, severe cases are being observed with up to 2 weeks of bed rest.

For many tinnitus patients, this means that with an infection, their tinnitus becomes louder and the intensity can no longer be reconciled with life. Furthermore, the number of new patients who are now developing tinnitus and had no long-COVID effects from previous COVID infections has increased significantly.

The management of Resaphene estimates the proportion of depressed patients to currently be 30% and that of suicidal patients to be 10%. An increase in these numbers is foreseeable due to new infections.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company that was founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland

T. +41 714500668
a.rauterkus@resaphene.ch